A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

NCT03300921 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class

Stopped Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery

Conditions

Interventions

Sponsor

Abramson Cancer Center at Penn Medicine